Thirty percent of individuals with chromosome 22q11.2 deletion syndrome (22q11.2DS) develop a psychotic disorder, particularly schizophrenia. We assessed attenuated positive, negative and disorganized symptoms of psychosis and clinical-high-risk syndromes in 20 adolescents with 22q11.2DS (median age 15.1 years) using the Structured Interview for Prodromal Symptoms (SIPS). Two participants met criteria for the Attenuated Positive Symptom Syndrome, while nine participants (45%) experienced positive symptoms rated in the "moderate" to "severe and psychotic" range on the SIPS. Almost all presented with moderate to severe symptoms in the negative, disorganized, and general symptom domains.
Introduction
Mental disorders are common in chromosome 22q11.2 deletion syndrome (22q11.2DS), which is caused by a microdeletion at chromosomal region 22q11.2 (OMIM accession nos. 188400, 192430, and 145410) . Psychotic disorders, especially schizophrenia, have a lifetime prevalence of about 30% (Murphy and Owen, 2001) , which is disproportionately high with respect to other neurodevelopmental disorders (Gothelf et al., 2008) .
Given this genetic risk, researchers have assessed symptoms of psychosis in adolescents with 22q11.2DS. Using general psychopathology interviews, four studies have reported positive symptoms of psychosis in 14-48% of youth with 22q11.2DS (Baker and Skuse, 2005; Debbane, et al., 2006; Feinstein, et al., 2002; Vorstman, et al., 2006) . However, examining subclinical psychotic-like symptoms may yield additional information about the presentation of psychosis in this at-risk population. Consequently, Baker and Skuse (2005) studied schizotypal personality disorder symptoms in adolescents with 22q11.2DS. While 48% (n = 12/25) reported transient psychotic-like symptoms, 84% (n = 21/25) endorsed at least one schizotypal symptom. They hypothesized that subclinical, schizophrenia-related symptoms may be much more common in adolescents with 22q11.2DS than the lifetime prevalence of schizophrenia in 22q11.2DS.
The Structured Interview of Prodromal Symptoms (SIPS) was developed (McGlashan, 2001 ) and validated (Miller, et al., 2002; Miller, et al., 1999) to assess the presence of subclinical schizophrenia-related symptoms, including attenuated psychotic symptoms (APS), in help-seeking populations. SIPSdefined clinical-high-risk (CHR) syndromes are associated with increased risk for schizophrenia (Miller, et al., 2002) . In a large multicenter longitudinal study, CHR syndromes predicted the development of psychosis in 35% of 291 participants over a 2 year follow-up period (Cannon, et al., 2008) .
We hypothesized that adolescents with 22q11.2DS would demonstrate high rates of attenuated positive symptoms (APS) and other schizophrenia-related symptoms on the SIPS. Unlike general psychopathology interviews used in previous studies (Baker and Skuse, 2005; Debbane, et al., 2006; Feinstein, et al., 2002; Vorstman, et al., 2006) , the SIPS directly assesses attenuated symptoms that are reliably associated with increased clinical risk for schizophrenia.
Methods

Participants
Our study was approved by the UCDHS Institutional Review Board. We recruited from a pool of participants in cognitive studies at the UCDHS M.I.N.D. Institute's Cognitive and Brain Imaging Laboratory (CABIL) and advertised as "Psychopathology in Chromosome 22q11.2 Deletion Syndrome" on the CABIL website.
We recruited 22 participants, ages 12-22 years, with 22q11.2DS. Each participant provided a record of fluorescence in situ hybridization verified chromosome 22q11.2 deletion. Participants and their guardians provided study assent and consent respectively. Participants were excluded if they had a history of traumatic brain injury, past or current psychotic disorder (n = 1) or mood disorder with psychotic features, illicit substance use in the month prior to assessment, or IQ below 50 (n = 1). Twenty were eligible for the analysis. No participant tested positive for current substance use based on urine dipsticks (Phamatech, San Diego, CA).
Procedures
The SIPS (McGlashan, 2001) contains the Scale of Prodromal Symptoms (SOPS) that rates 19 schizophrenia-related symptoms on a 6-point scale within into four domains: positive, negative, disorganized, and general. The SIPS Criteria of Prodromal Syndromes (COPS) determines the presence of a CHR syndrome. SOPS positive symptoms rated at a 3-5 severity level are within the attenuated range. We report Global Assessment of Functioning (GAF) scores based on the SIPS revision (Hall, 1995; Miller, et al., 1999) . The Schedule for Affective Disorders and Schizophrenia for School Aged Children, Present and Lifetime (KSADS-PL) (Kaufman, et al., 1997) was used in conjunction with the SIPS to specify comorbid mental disorders. As the KSADS-PL does not directly assess autistic symptoms, a diagnosis of a pervasive developmental disorder was according to the Diagnostic and Statistical Manual, 4th Edition, Text Revised (DSM-IV-TR) (American Psychiatric Association, 2000).
Participants and their caregivers both completed live clinical interviews. Following a general clinical interview tailored to 22q11.2DS (available on request), JS, a board-eligible psychiatrist, conducted the KSADS-PL and SIPS according to their instructions. Interviews were videotaped for review. JS and RH reviewed the clinical interview, KSADS-PL interview, and intelligence tests to determine DSM-IV diagnoses. Interviewer reliability for SIPS administration and scoring (for JS and TN) was established through standardized training (Miller, et al., 2003) , both showing agreement with a Cohen's kappa greater than 0.80. Interviews were reviewed by JS and TN and consensus scores were created across all SIPS scales and syndromes.
Intelligence was assessed by M.I.N.D. Institute Assessment Core staff using the current, age-appropriate Wechsler intelligence instrument (Wechsler, 1997 (Wechsler, , 2004 . Because of its association with schizophrenia (Muntaner, et al., 2004) , socioeconomic status (SES) was measured using Hollingshead's four factor index (Hollingshead, 1975) .
Statistical analysis
SOPS scores within each symptom domain were summed to create a total score for analysis. Domain total scores were logtransformed to improve normality. Linear regression was used to examine the effects of SES, intelligence, age, and GAF score on participants' four domain scores. Analyses were 2-tailed with alpha set at p ≤ 0.05 to allow for recognition of smaller effects due to small sample size.
Results
Participant demographic and clinical characteristics are listed in Table 1 . Participants presented with high rates of mental disorders (Table 2) . While comorbid diagnoses were common, 5 (20%) had experienced just one mental disorder during their lifetime, and 2 (10%) had no current or past mental disorder.
SOPS data are summarized in Table 3 . Nine individuals (45%) presented with APS. Participant's total positive symptoms ranged from 0 to 14. Moderate to severe symptoms in each of the negative, disorganized, and general symptom domains were also common. Two participants met criteria for SIPS "attenuated positive symptom syndrome." In both cases, the qualifying symptom was recent-onset auditory hallucinations beginning within the year prior to assessment and occurring at least once per week. Notably, no other positive symptom score was above the "questionably present" level for these two individuals, their total positive symptom scores were 4 and 5. In contrast, six of the remaining seven 22q11.2DS individuals reported long-standing APS symptoms and therefore did not meet criteria for a CHR syndrome. These six included those with the highest positive symptom total scores, 13, 13, and 14.
SOPS total scores across the four domains were not associated with age or intelligence. SES was inversely associ- ated with the positive domain (r = −0.51, p = 0.020); this strengthened after controlling for intelligence (r = −0.65, p = 0.005). This finding argues for inclusion of SES measures in future studies of the schizophrenia development in 22q11DS. GAF was inversely associated with negative, disorganized, and general domains only (respectively: r = −0.60, p = 0.005; r = −0.46, p = 0.044; r = −0.53, p = 0.017), which is expected given the overlap between these measures.
Discussion
This is among the first reports of APS in youth with 22q11.2DS assessed with the SIPS, a validated measure of APS. We found a high prevalence (45%) of APS in our sample, consistent with previous studies of psychotic-like symptoms (Baker and Skuse, 2005; Debbane, et al., 2006; Feinstein, et al., 2002; Vorstman, et al., 2006) . Our findings complement those of Rockers et al. (2009) who assessed an older group of nonpsychotic transitional adults with 22q11.2DS using the SIPS. In addition, moderate to severe symptoms across the other three schizophrenia-related symptom domains were common. Consistent with our hypothesis and the findings of Baker and Skuse (2005) , our participants presented with a wide array of subclinical, schizophrenia-related symptoms varying in degree of severity. Such symptoms were much more common than might be expected given the lifetime prevalence of psychotic disorders in 22q11.2DS.
We attempted to mitigate typical sources of bias. Though we exclude any participant with a prior diagnosis of psychotic disorder or mood disorder with psychosis, ascertainment bias is a limitation. We addressed observer bias by establishing consensus for each score between two reliable mental health professionals. Still, this study would have benefited from a comparison group, such as one comprised of other individuals at high risk of schizophrenia. Too few participants were taking antipsychotic medications (n =2) or had first degree relatives with psychotic disorders (n = 1) to statistically assess their impact. Participants' intelligence and mental disorders are consistent with prior studies reporting on the cognitive and behavioral phenotype of 22q11.2DS (Gothelf, et al., 2008) . The high rate of schizophrenia-related symptoms found in this study may be generalized to other clinical populations of adolescents with 22q11.2DS.
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